MRI增强扫描在弥漫性和间变性胶质瘤中的诊断价值
该回顾性研究从前瞻性数据库纳入99例首次切除的WHO II级和III级胶质瘤患者,用容积分割测量术前T1加权MRI的钆增强体积。间变性胶质瘤检出增强的OR为弥漫性胶质瘤的7倍(95%CI 2.8-17.2,p<0.0001);50%(8/16)局灶间变性和28%(10/36)完全间变性胶质瘤无增强,21%(10/47)弥漫性胶质瘤有增强。
要点
- 间变性胶质瘤检出增强的OR为弥漫性胶质瘤的7倍(95%CI 2.8-17.2,p<0.0001)。
- 50%(8/16)局灶间变性和28%(10/36)完全间变性胶质瘤无增强。
- 21%(10/47)弥漫性胶质瘤存在增强。
核心结论
- 增强与间变、IDH1野生型和ATRX表达等不良预后特征的高比值比相关。
- 四分之一间变性胶质瘤和一半局灶间变性胶质瘤无增强。
研究设计与样本
- 回顾性从前瞻性数据库检索99例首次切除的WHO II级和III级胶质瘤患者。
- 用容积分割测量术前T1加权MRI的钆增强体积。
主要发现
- 间变性胶质瘤检出增强的OR为弥漫性胶质瘤的7倍(95%CI 2.8-17.2,p<0.0001)。
- 50%(8/16)局灶间变性和28%(10/36)完全间变性胶质瘤无增强。
- 21%(10/47)弥漫性胶质瘤存在增强。
- 间变与更大的增强体积相关(r=0.49,p<0.0001),相比完全弥漫性肿瘤额外提供4 cm3增强体积。
- IDH1野生型肿瘤有增强的OR为3.6倍(95%CI 1.3-10.2,p=0.05),ATRX表达肿瘤为4.8倍(95%CI 1.3-17.2,p=0.05)。
关键数值与推荐
- 间变性胶质瘤检出增强的OR为7(95%CI 2.8-17.2,p<0.0001),对比弥漫性胶质瘤。
- IDH1野生型肿瘤有增强的OR为3.6(95%CI 1.3-10.2,p=0.05)。
- ATRX表达肿瘤有增强的OR为4.8(95%CI 1.3-17.2,p=0.05)。
- 间变与增强体积相关r=0.49(p<0.0001),额外4 cm3增强体积对比完全弥漫性肿瘤。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated differentiations in gadolinium contrast enhancement (CE) between low-grade WHO °II and high-grade WHO °III gliomas in conventional MRI, which have been repeatedly questioned. METHODS: Ninety-nine patients, who underwent first resection of WHO°II and °III gliomas, were retrospectively retrieved from a prospective database. The quantitative metric volume of Gd-CE in T1-weighted pre-operative MRI was measured using volumetric segmentation. RESULTS: The OR to detect CE in anaplastic gliomas was seven times higher than that in diffuse gliomas (CI95% 2.8-17.2, p<0.0001). No CE was seen in 50% (8/16) of focal anaplastic and in 28% (10/36) of entirely anaplastic gliomas. CE was present in 21% (10/47) of diffuse gliomas. Anaplasia correlated with a larger CE volume (r=0.49, p<0.0001) and provided additional 4 cm3 of CE volume compared to entirely diffuse tumors. The OR to have CE was 3.6 times for IDH1 wild-type tumors (CI95% 1.3-10.2, p=0.05) and 4.8 for tumors with ATRX expression (CI95% 1.3-17.2, p=0.05). In all sub-groups, at least a quarter of cases showed no CE at all and there were cases with present CE. CONCLUSION: CE is associated with higher odds of unfavorable prognostic features like anaplasia, wild-type IDH1 and retained ATRX. There was no CE in one-fourth of anaplastic gliomas and half of gliomas with focal anaplasia.
引用
- Krigers A, Demetz M, Grams AE, et al. The diagnostic value of contrast enhancement on MRI in diffuse and anaplastic gliomas. Acta Neurochir (Wien). 2022. PMID: 35018531. doi:10.1007/s00701-021-05103-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。